Oncotarget Publishes a Study Proving Candidiasis Can Lead to Cancer

Oncotarget released a study proving that a candida-based infection increases the risk of patients developing cancer. This study is groundbreaking because it warns that controlling the spread of candida is necessary to help save lives and help prevent cancer later on. Candida may be a good warning sign of when preventative measures are critical to stop cancer before it develops. A majority of doctors have already noted that recurring yeast infections precede diabetes, AIDS and leukemia.

What is candidiasis?

Most people are familiar with candidiasis by other names such as “yeast infections” or “thrush.” However, the troublesome part of candida overgrowth is how many people suffer from it without realizing it. Candida overgrowth is so common that Julia Koehler from Harvard University showed candida is the primary contributor of fungal infections, responsible for 60 percent of all fungal-based infections in U.S. hospitals and causing the deaths of a third of those after reaching their bloodstream. Plus, in America and Europe, almost 75 percent of all adult women contract vaginal yeast infections at least one time in their lives.This fungal infection comes from more than 15 different kinds of yeasts, of which Candida albicans is the most prevalent. While everyone has some amount of this yeast naturally, its overgrowth and rapid spreading are what lead to infections. Typically candida infections appear in warm, moist areas of the body like the mouth, genitals, esophagus, gastrointestinal tract, liver, respiratory tract and skin. Candida also grows quickly when it reaches the bloodstream, eyes, brain, heart, kidneys and spleen.

Candida infections often show up when:

  • the immune system becomes weak
  • taking antibiotics, steroids or birth-control pills for a prolonged amount of time
  • abusing drugs
  • the liver isn’t functioning well
  • someone is deficient in nutrients
  • a woman is pregnant

Who participated in this study?

A total of eight different doctors and researchers in Taiwan came together to conduct this study. They work at the Zuoying Branch of Kaohsiung Armed Forces General Hospital, the Department of Bioinformatics and Medical Engineering at Asia University, the Graduate Institute of Clinical Medical Science in Taichung, the Department of Radiation Oncology at China Medical University Hospital and the National Management Office for Health Data at the same university.They collected data from 34,829 patients using the database of the National Health Insurance system of Taiwan for this study. They selected the subjects completely at random. To create a control group, they matched each person with candidiasis with a person from Taiwan’s general population who never had the candida-overgrowth infection using the basic data of gender, age and other standard criteria like monthly income, residence location and similar chronic health issues. Some health issues often occur with candidiasis, so researchers compared people with and without candida infections who had these same problems:

  • connective tissue disease
  • hypertension
  • drug dependence
  • diabetes
  • chronic obstructive pulmonary disease
  • hyperlipidemia
  • chronic renal failure
  • coronary artery disease
  • chronic liver failure
  • HIV infection
  • inflammatory bowel disease

The average age of the participants in the study was 40 years old. Each subject was at least 20 years old or older and had received a diagnosis of candida infection from the beginning of the year 2000 through the end of the year 2012. These people mostly had candidiasis of the mouth or urogenital sites, although some had infections in other areas. It’s important to note that none of the people included in the study had ever had cancer before having a candida infection. Using the Registry for Catastrophic Illness Patient Database, researchers followed the progress of patients from their dates of diagnosis until they developed cancer, died or withdrew from the national program due to health improvement up until the end of 2013.For this study, they used 10 times as many woman as men since genital yeast infections are one of the most-common types of candida. Doctors wondered if the cancers developed were specific to the sites of the original candida infections, so they analyzed the subjects further and compared their sites of infections to the sites where cancer appeared later. They found that those with candidiasis of the mouth had a greater risk of developing any kind of cancer, with the exception of lip and pancreatic cancers. By contrast, those with candidiasis of the genitals had a much smaller risk of developing any type of cancer.

What were the results?

Results clearly showed that those with candida infections had a much higher chance of cancer overall. Additionally, those who suffered from candida infections seemed more likely to get cancer in their head, neck, thyroid, pancreas or skin. Specifically, they had higher risks for developing non-Hodgkin’s lymphoma, myeloid leukemia and other oral-cavity cancers. On average, 17 percent more of the subjects who had candida infections got cancer later compared to those who never had candida overgrowth.The study confirms a similar investigation in Denmark linking candida infections with oral cancers. Sometimes cancer-related therapies lead to candida infections as well.

Some exceptional differences to note were that candida patients had:

  • three times as many cases of skin cancer
  • twice as many cases of Non-Hodgkin’s lymphoma
  • twice as many cases of thyroid cancer

How long was it before those with candida infections developed cancer?

It appears that each cancer behaved differently, having distinctive onset times. Within one year after their candida infection, people were more likely to get non-Hodgkin’s lymphoma. Within five years after their candida infection, people were four times more likely to get thyroid cancer. After five years since their candida infections, people were six times more likely to get skin cancer.

How do researchers believe the disease process of candida infections leads to cancer?

While it could occur in several ways, doctors analyzed data from several previous studies as well and saw several points in common. Doctors found that candida produces carcinogens like nitrosamines, often found in subjects with oral cancer. Furthermore, candida overgrowth creates a large-scale inflammatory response in the body. Tumors grow in environments with lots of inflammation and require this kind of environment to thrive.

If you don’t know, here’s a brief history of Oncotarget:

Oncotarget is an expert source of online medical publications, and they specialize in delivering some of the most-exciting research developments in cancer studies and treatments. They also focus on the studies of related fields like general pathology, immunology, physiology, endocrinology and age-related diseases. They chose the word “oncotarget” to represent all the various molecules, disease pathways and other cellular functions commonly found in cancer and other kinds of neuro-degeneration.Oncotarget is one distinctive medical journal in that it’s multidisciplinary and offers free access to the public. They now release weekly, printable issues.Oncotarget is part of Impact Journals LLC, started by Editors in Chief Andrei V. Gudkov and Mikhail V. Blagosklonny. Both of these men are from the Roswell Park Cancer Institute in Buffalo, New York. Oncotarget’s original editorial board contains 48 top cancer-research specialists from institutions nationwide, as well as from Europe and the United Kingdom.

Cancer Treatment Centers of America Helps People Learn The Statistics

Among the things people need to know about cancer is the statistics of each cancer. After all, different forms of cancer have different rates of survival. This is one of the reasons that Cancer Treatment Centers of America are willing to provide this type of information. After all, people who have knowledge have more of the tools needed to move forward with the needed treatment. This is one thing that is going to make the difference in the lives of the patient that is suffering from cancer. The only thing is that the patient has to be willing to take the necessary steps to treat the cancer and at least reduce the damages that it does.

Cancer Treatment Centers of America is one of the facilities that are going to equip people with the tools that they need to be prepared for if they detect cancer in their bodies. Among the things they will have listed is information on each cancer including the symptoms that come with it. They will also provide people with what it is going to take to effectively treat it and the side effects of the treatment. With the right type of preparation, the patient is going to be able to get through the cancer and come out stronger. Visit https://www.myctca.com/ to know more about CTCA.

When it comes to cancer, knowledge is power. It is very important for even people who do not have cancer to learn everything they can about the cancer disease. After all, there is no telling whether or not they are going to have cancer or when they are going to get it. Also, one can’t predict at what stage it is going to be in before it is detected in the person. Fortunately, the individual has access to a lot of the effective treatments that they could use for their recovery.

For more information follow CTCA on Twitter.

Rutgers Cancer Institute Launches the Omar Boraie Chair in Genomic Science

The newly established Omar Boraie Chair in Genome Science at Rutgers Cancer Institute of New Jersey will help to propel groundbreaking research in precision medicine, http://patch.com/new-jersey/newbrunswick/omar-boraie-chair-genomic-science-established-rutgers-cancer-institute. Endowed chairs are considered gold standards in higher education because they express the commitment that universities have put on growing academic disciplines at the highest levels, and ensure their continued support.

The Rutgers Cancer Institute chair is named for philanthropic New Brunswick real estate developer, Omar Boraie. The developer has pledged to donate $1.5 million to support it. The Omar Boraie Chair is part of the “18 Chair Challenge,” a campaign by Rutgers University. In the campaign, an anonymous donor provides $1.5 million to match each of the 18 new chairs. The result is a total endowment of $3million. Rutgers Cancer Institute of New Jersey is a comprehensive cancer center with a national status.

Evolving Precision Medicine

Precision medicine and genomic science fields are changing the approach of medical doctors towards the diagnosis of cancer and its treatment. The relatively new field involves genetic-level treatment and analysis of cancerous tumors, which allows oncologists to prescribe individualized therapies correctly. The importance of precision medicine was attested during the recent state of the Union Address by President Barrack Obama. In the speech, the president proclaimed the launch of a nationwide precision medicine initiative.

Although presently several cancer research centers are performing next-generation gene sequencing, the Rutgers Cancer Institute was a national pioneer in the field. Genomic sequencing has been instrumental in coming up with novel therapies that help people with poor prognoses, rare cancers, and those with limited treatment options. Precision medicine advancements have allowed the classification of cancers into subpopulations sharing similar characteristics although they have different genetic make-up.

Omar Boraie said that he was happy with the work done at Rutgers Cancer Institute because it has made advances in precision medicine, especially for non-responsive patients. He wondered how awesome it would be if the science were applied to everybody suffering from cancer. He concluded by saying that he was hopeful that his family’s $1.5 million pledge would inspire other well-wishers to come out and support the cause.

Rutgers Institutes’ Director, Robert S. DiPaola, MD, said that the entire institute was grateful to Boraie’s generosity and support. He added that Boraie was an integral part of New Brunswick’s development as a “Healthcare City.” Shridar Ganesan, a principal investigator at the Rutgers Institute, was named to the Omar Boraie Chair. He is a medical oncologist who is also internationally renowned as a top academic leader and researcher.

An innovative Way to Treat Cancer with Clay Siegall at Seattle Genetics

With an innovative scientific method and research capabilities behind creating an antibody-drug conjugate, Seattle Genetics has proved itself to be an innovative company that is truly dedicated to helping individuals around the world have a new method for killing cancer without putting toxins in the body. Seattle Genetics was founded in 1998 by Clay Siegall, a leader in the science community who has had years of professional experience with development and research. As the President as well as the CEO of this company, Clay Siegall co-founded this company in order to offer individuals a new therapeutic method to treating cancer. This biotechnology company not only specializes in developing innovative scientific discoveries, but also specializes in commercializing each product that is made to the public. As a company that is currently the leader of an antibody-drug conjugate, Dr. Clay Siegall and his employees have received awards and recognition for their excellent work and research within the industry of science.

The antibody-drug conjugate is a treatment for cancer without the harmful effects that can come from radiation or even from chemotherapy. As an ADC, this conjugate is designed to target monoclonal antibodies. In doing this, the ADC delivers cell-killing agents that are designed to target the cancer cells without harming other cells within the body. This innovation leads to a healthier outcome within the body. The use of ACDs has been approved in over 60 countries and has helped millions of individuals with cancer. In collaboration with Takeda Pharmaceutical Company Limited, the two have continuously negotiated with other countries in order to spread this treatment to other countries in need of a cheap solution.

Above all, the main goal of this company is to help people who have suffered from cancer. With a corporate culture, this company has successfully valued integrity, scientific excellence, innovation, and even team work. As the acknowledged leader of the antibody-drug conjugate, this company hopes to expand more into the future. Clay Siegall states that the reason behind his decision to create this product is to offer a new and non-toxic way to treat cancer without ever having to break the bank.

Learn More:

https://twitter.com/seattlegenetics

http://people.equilar.com/bio/clay-siegall-seattle-genetics/salary/42318#.V3_Y2Y6RKGg

The New ADC Treatment by Seattle Genetics

For anyone who has had cancer or who has experienced a loved one suffer or die from the disease, they understand how the condition affects the patient and leaves them in a bad state. Treating cancer is not an easy thing to do. Medical researchers have made strides in finding a cure for cancer but there is still a long way to go in terms of finding lasting treatment solutions.

While there are many researches underway, there are however, many innovations in the biotechnology field. One of them is the recent treatment option by Seattle Genetics a biotechnology company located in the United States. The company has come up with a treatment technology known as ADC. ADC, which stands for Anti-body drug conjugate, is a technology which uses agents to kill cancer cells in the body.

The concept behind the treatment by ADC technology is that the patient is not subjected to the horror that comes with chemotherapy. They are able to recover faster since the therapy does not harm the normal and unaffected cells. The agents only kill the cancer cells living the normal ones to thrive. The treatment is one of the best methods of slowing the effects of cancer and ensuring that patients recover faster.

  1. Clay Siegall is the CEO and founder of Seattle Genetics. He is the brain behind the company and he has done a lot to ensure that the company provides the best innovative technologies in the field of biomedicine. What most people do not know about Mr. Siegall is that apart from being the founder of Seattle Genetics, he is also a researcher. He is a scientist whose area of specialty is therapies. He is also an enthusiast of drug research and treatments.

AT Seattle Genetics, there is a team of experts who work around the clock to make sure that they come up with therapies and treatment technologies for many diseases. They have a passion for those suffering from various medical conditions including cancer. With their dedication and expertise, they have helped patients get efficient and effective treatment for cancer.

Learn more:
http://www.seattlegenetics.com/clay_siegall

http://seekingalpha.com/article/3969434-seattle-genetics-sgen-clay-b-siegall-q1-2016-results-earnings-call-transcript